- Home
- GALT vs LXEO Comparison
GALT vs LXEO Comparison
Compare GALT & LXEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GALT | LXEO |
|---|---|---|
| Founded | 2000 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 397.3M | 348.7M |
| IPO Year | 2008 | 2023 |
Fundamental Metrics
Financial Performance| Metric | GALT | LXEO |
|---|---|---|
| Price | $3.49 | $3.13 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $20.30 |
| AVG Volume (30 Days) | 197.8K | ★ 1.5M |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 36.84 | ★ 39.81 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $654,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.03 | $2.55 |
| 52 Week High | $7.13 | $10.99 |
Technical Indicators
Market Signals| Indicator | GALT | LXEO |
|---|---|---|
| Relative Strength Index (RSI) | 45.36 | 45.43 |
| Support Level | $2.71 | $2.98 |
| Resistance Level | $3.56 | $3.68 |
| Average True Range (ATR) | 0.23 | 0.24 |
| MACD | -0.02 | 0.06 |
| Stochastic Oscillator | 41.34 | 63.92 |
Price Performance
Historical ComparisonAbout GALT Galectin Therapeutics Inc.
Galectin Therapeutics Inc is a clinical-stage biopharmaceutical company. The company focuses on drug research and development to create new therapies for fibrotic disease, cancer, and selected other diseases. Its galectin-3 inhibitor is belapectin (GR-MD-02), which has been demonstrated in preclinical models to reverse liver fibrosis and cirrhosis.
About LXEO Lexeo Therapeutics Inc.
Lexeo Therapeutics Inc is a clinical-stage genetic medicine company engaged in the development of gene therapy candidates targeting the underlying genetic causes of cardiovascular diseases. The company is advancing a portfolio of programs focused on conditions such as Friedreich ataxia, cardiomyopathy, plakophilin-2, or PKP2, and arrhythmogenic cardiomyopathy, with its lead candidates including LX2006 and LX2020. Its therapies utilize AAV-based vectors designed to deliver functional genes to cardiac cells to restore normal function and address high unmet medical needs.